Valopicitabine (NM-283) is an antiviral drug which was developed as a treatment for hepatitis C, though only progressed as far as Phase III clinical trials.

It acts as an RNA-dependent RNA polymerase inhibitor.

It is a prodrug which is converted inside the body to the active form, 2'-C-methylcytidine triphosphate.

[1][2][3][4][5] This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.